Description
Summary Abstract
SLU-PP-332 (pan-ERR agonist; Saint Louis University / University of Florida compound) is a synthetic small-molecule exercise mimetic that acts as a potent agonist across all three estrogen-related receptor (ERR) isoforms — ERRα, ERRβ, and ERRγ. By preferentially activating ERRα (EC50 98 nM) and engaging the downstream peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) transcriptional cascade, SLU-PP-332 recapitulates the genetic signature of sustained endurance training in skeletal muscle, liver, and cardiac tissue. Preclinical murine studies have demonstrated a 12–20% reduction in fat mass, 50% improvement in insulin sensitivity, and a 70% increase in treadmill endurance duration without changes in food intake. Emerging cardiovascular data indicate cardioprotective effects in pressure-overload heart failure models, positioning SLU-PP-332 as a candidate for metabolic syndrome, sarcopenia, and cardiac insufficiency research.
Clinical Indications
Preclinical evidence supports investigation in the following contexts:
- Obesity and Metabolic Syndrome: Diet-induced obese murine models show SLU-PP-332 reduces fat mass by 20% and fasting glucose by 30% via elevated basal energy expenditure and enforced fatty acid oxidation.
- Sarcopenia and Muscle Atrophy: ERRα-driven upregulation of oxidative (Type IIa) muscle fiber composition and mitochondrial biogenesis supports investigation in age-related and disuse-related muscle wasting.
- Heart Failure: In pressure-overload murine models, SLU-PP-332 improved ejection fraction, reduced cardiac fibrosis, and increased survival by restoring myocardial fatty acid metabolism and mitochondrial energy production.
Contraindications
- Pre-existing Cardiac Hypertrophy: ERRγ activation via the GATA4 pathway may exacerbate pathological cardiac hypertrophy in subjects with established hypertrophic disease; a 25% increase in heart-to-body weight ratio has been observed in healthy murine models at therapeutic doses.
- Hepatic Impairment: Doses ≥100 mg/kg in murine models produced elevated ALT/AST, indicating dose-dependent hepatotoxicity risk that warrants caution in any model with baseline liver pathology.
- Chronic Glycogen Depletion States: Forced PDK4-mediated inhibition of the pyruvate dehydrogenase complex and 12-week continuous dosing led to muscle glycogen depletion in animal studies; concurrent glycogen repletion monitoring is indicated.
Mechanism of Action (MOA)
SLU-PP-332 engages the ERR/PGC-1α axis to drive a coordinated transcriptional program mirroring endurance exercise adaptation:
Pan-ERR Agonism
SLU-PP-332 binds and activates all three estrogen-related receptor isoforms (ERRα, ERRβ, ERRγ), with preferential potency at ERRα (EC50 98 nM vs. 215–430 nM for ERRγ). ERRs are orphan nuclear receptors that govern transcription of metabolic gene networks in high-energy tissues including skeletal muscle, heart, and liver.
PGC-1α Cascade Activation
Activated ERRα recruits PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of endurance exercise adaptation. The ERRα/PGC-1α complex drives expression of genes governing mitochondrial biogenesis, fatty acid transport (CPT1A, ACOX1), and oxidative phosphorylation, producing a 2.5-fold increase in skeletal muscle mitochondrial DNA in murine models.
Metabolic Substrate Switching
Upregulation of PDK4 (pyruvate dehydrogenase kinase 4) — a direct ERR target gene — inhibits the pyruvate dehydrogenase complex, effectively reducing glucose utilization as a primary energy substrate and redirecting cellular metabolism toward fatty acid oxidation. This mechanism underlies the compound’s anti-obesity and insulin-sensitizing effects observed in diet-induced obese models.
Skeletal Muscle Remodeling
Chronic ERR/PGC-1α activation increases the proportion of oxidative Type IIa muscle fibers — mitochondria-rich, fatigue-resistant fibers characteristic of endurance-trained phenotypes. This structural remodeling provides the physiological basis for the 45–70% increase in treadmill endurance observed in treated murine models without loss of lean mass.
Key Features & Specifications
SLU-PP-332 is distinguished by the following characteristics within the exercise mimetic research category:
Chemical Analysis
| Property | Specification Reference Data |
|---|---|
| IUPAC Name | 2-chloro-4-[[(1R,2S)-2-hydroxycyclopentyl]amino]-N-[4-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide (representative scaffold; confirm per CoA) |
| CAS Number | 2183627-52-1 |
| Molecular Formula | C17H16ClF3N4O2 |
| Molecular Weight | 404.78 g/mol |
| PubChem CID | 137700913 |
| Synonyms | SLU-PP-332; pan-ERR agonist SLU332 |
| Form / Variation | 250 MCG Capsules (SKU C-039) / 500 MCG Capsules (SKU C500-040) / 15 MG Capsules (SKU C-055) / 300 MCG/mL Liquid (SKU L-018) |
Storage, Safety, and Handling
Storage Protocol
Capsule forms should be stored at 2–8 °C in a sealed container, protected from light and moisture. The liquid formulation (300 MCG/mL) must be kept refrigerated at 2–8 °C and used within the manufacturer’s indicated stability window; do not freeze. Once opened, document date and maintain cold-chain integrity throughout the storage period.
Handling & Compliance
SLU-PP-332 is an investigational small molecule; standard laboratory personal protective equipment (PPE) — gloves, eye protection, lab coat — is appropriate for handling. The compound is classified by the World Anti-Doping Agency (WADA) within categories relevant to metabolic modulators and exercise mimetics; investigators should consult current WADA prohibited list documentation when designing studies involving athletic populations. No validated human pharmacokinetic data are currently available.